Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …

The acute respiratory illnesses caused by severe acquired respiratory syndrome corona
Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people …

This guidance focuses on methodological aspects of lupus anticoagulant (LA) testing, as
well as interpretation of results for clinicians. The main changes in how to test for LA …

Background High incidence of thrombosis in COVID‐19 patients indicates a
hypercoagulable state. Hence, exploring the involvement of antiphospholipid antibodies …

Currently, we use the classification criteria for antiphospholipid syndrome (APS) formulated
during the consensus conference in Sapporo and revised in Sydney 1. Classification criteria …

Diagnosis of antiphospholipid syndrome (APS) requires the presence of a clinical criterion
(thrombosis and/or pregnancy morbidity), combined with persistently circulating …

Essentials• The clinical value of IgM antibodies in thrombotic antiphospholipid syndrome
(APS) is debated.• By review of literature, we reconsidered the clinical value of IgM …

Background The antiphospholipid syndrome (APS) is characterized by thrombosis and/or
pregnancy morbidity with the persistent presence of lupus anticoagulant (LAC), anti …

The term “lupus anticoagulant (LA)” identifies a form of antiphospholipid antibodies (aPLs)
causing prolongation of clotting tests in a phospholipid concentration-dependent manner …

Background Antiβ2glycoprotein I (aβ2GPI) and anticardiolipin (aCL) IgG/IgM show
differences in positive/negative agreement and titers between solid phase platforms. Method …